US FDA gives CordenPharma Latina's Italian plant the all clear

By Gareth Macdonald contact

- Last updated on GMT

Google Maps
Google Maps
CordenPharma Latina has resolved the problems that earned its API and injectable drug facility in Sermoneta, Italy a warning letter from the US FDA last year.

The US regulator gave the plant a clean bill of health in a closeout letter​ this month, explaining that: “Based on our evaluation, it appears that you have addressed the violations and or deviations.”

The Sermoneta facility – which was previously owned by Bristol Myers - makes oral and sterile liquid dosage forms antibiotics, including cephalosporin and penicillins. It was also cleared to manufacture freeze-dried cancer drugs for clinical trials in July 2015.

CordenPharma – which is owned by Germany-based International Chemical Investors Group (ICIG) – said addressing the issues – which were detailed in a warning letter in May​ last year – had involved a “holistic and systematic approach​.”

The firm declined to comment further when contacted by in-Pharmatechnologist.com.

Related news

Show more

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers